0
个在招岗位
0
个在招岗位
Biocomposites develops, manufactures and markets synthetic calcium composite devices for tissue regeneration.
Leading edge, proprietary technologies are bioengineered to mimic in-vivo the composite structure of human bone.
Biocomposites' technologies, developed over more than a decade of research, have been designed by a team of bioceramic
and medical polymer specialists with a combined experience of more than fifty years.
Bilok composite, represents the biomedical fields' first synthetic calcium based technology in sports medicine to
receive CE Mark and approval by the U.S. Federal Food and Drug Administration.
Next generation biomaterials such as Bilok® and fortoss Vital® represent a major breakthrough in the
treatment of bone disorders and soft tissue injuries.
Biocomposites' absorbable devices are used globally by surgeons and clinicians to regenerate bone in fractures,
spinal fusions and in cases involving bone loss due to trauma, disease or surgery.
Our on-going research and development programmes are co-ordinated with universities and hospitals
internationally to engineer new synthetic, absorbable scaffolds for the regeneration of bone and cartilage tissue.
Biocomposites是由英国著名的Jesse Shirley公司在1992年分离组建出来的专业从事人工合成医用材料的公司。
公司在开发以钙基为基础的可吸收的医用人工合成材料上有着卓越的技术和丰富的经验。经过十年的努力,
公司已经成功的开发出了一系列优化的生物医用材料和产品。Biocomposites 的技术和医疗产品大大降低了
手术的成本和病人再次手术的痛苦。我们的技术突破了当前的传统医疗技术,受到了大部分外科医生的认可和好评。
总公司在美国设立了分公司-------Biocomposites.INC.USA, 为了进一步开拓亚太地区市场,由总公司投资
在中国上海设立了分公司-----Biocomposites Shanghai Ltd(百赛上海有限公司)。目前上海分公司主要负责
骨科可吸收生物材料在亚太地区的市场和销售业务。